Table 1 Description of patients and controls
From: Cartilage oligomeric matrix protein-induced complement activation in systemic sclerosis
lcSSc baseline | lcSSc second sample | dcSSc baseline | dcSSc second sample | Controls | |
|---|---|---|---|---|---|
Number | 40 | 40 | 40 | 40 | 97 |
Age, years median (range) | 47.5 (16 to 77) | 50 (21 to 81) | 51.5 (22 to 77) | 56 (26 to 80) | 45 (23 to 74) |
Gender, female:male | 33:7 | 33:7 | 28:12 | 28:12 | 67:30 |
COMP, U/l median (range) | 9.3 (4.2 to 27.9) | 9.7 (3.9 to 15.8) | 16.0 (6.2 to 37.2) | 10.9 (5.0 to 30.0) | 7.0 (3.2 to 12.1) |
Disease duration, years median (range) | 1.4 (0.2 to 3.0) | 5.0 (3.2 to 7.1) | 1.0 (0.3 to 3.0) | 4.6 (3.3 to 7.5) | Not applicable |
COMP-C3b, AU median (range) | 2.5 (0.4 to 6.4) | 1.9 (0.8 to 6.1) | 2.3 (0.2 to 3.8) | 1.7 (0.7 to 4.0) | 0.6 (0 to 4.4) |
mRSS median (range) | 5.0 (2.0 to 19.0) | 3.0 (0 to 15.0) | 22.5 (3.0 to 43.0) | 12.5 (0 to 33.0) | Not applicable |
CRP, mg/l median (range) | 5.0 (0.8 to 79.0) | 4.0 (0 to 72.0) | 9.9 (0.8 to 91.0) | 4.9 (0.6 to 74.0) | nd |
ERS, mm/h median (range) | 11.0 (2.0 to 92.0) | 14.0 (3.0 to 60.0) | 18.0 (4.0 to 50.5) | 20.0 (2.0 to 66.0) | nd |
Immunosuppressant AZA:CYC:MTX:MMF | 1:1:1:0 | 12:0:2:3 | 1:2:2:0 | 12:1:2:8 | |
Prednisolon, yes:no | 7:32 | 11:28 | 13:25 | 13:25 | |
ANA, positive:negative | 31:9 | 29:11 | nd | ||
ENA, positive:negative | 10:30 | 10:30 | nd | ||
ACA, positive:negative | 10:30 | 1:39 | nd | ||
ATA, positive:negative | 3:32 | 7:29 | nd | ||
5 unknown | 4 unknown | ||||
ARA, positive:negative | 0:27 | 6:25 | nd | ||
13 unknown | 9 unknown |